Skip to content

Compounds · Immune · Antimicrobial and wound healing agent

LL-37 (CAP-18)

Full protocol

hCAP-18, CAMP, Cathelicidin LL-37, Human Cathelicidin, FALL-39

Naturally occurring 37-amino-acid antimicrobial peptide from the human cathelicidin family, discovered in 1995, active against bacteria, viruses, and fungi as part of innate immunity. Also promotes wound healing, resolves inflammation, and attracts immune cells; synthetic versions are being studied for resistant infections and chronic wounds.

0.1–0.5 mg every other day

Research score 75/100. Reference only, not a prescription.

  • Immune Boosting
  • Anti-bacterial
  • Anti-viral
  • Wound Healing
  • Inflammation Resolution
  • Anti-inflammatory
US status
Research Chemical
Approval
Research Chemical Only
Evidence
Human Cathelicidin antimicrobial peptide. Promotes wound healing and modulates immunity. Investigational for venous leg ulcers.
Research score
75 / 100
Indication
Research Only - No Medical Indication
Origin
Sweden
Source category
Immune System
Status group
Research chemical

Mechanism

Disrupts microbial membranes via electrostatic attraction and pore formation; also binds FPRL1 and P2X7 receptors on immune cells to recruit neutrophils, monocytes, and T cells, activates dendritic cells via TLR signaling, aids epithelial migration through EGFR transactivation, and neutralizes bacterial endotoxin.

Safety file

Narrow therapeutic window due to toxicity at high concentrations; may worsen autoimmune conditions like psoriasis or lupus through inflammation. Topical use is safe; systemic use is limited by toxicity.

  • Local injection site reactions
  • Temporary immune system activation
  • Potential inflammatory response

Reconstitution

Concentration by vial size and water volume
Vial2 mL water3 mL water
5 mg2.5 mg/mL1.67 mg/mL
  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • 0.1 mg to 0.5 mg (100 to 500 mcg) per dose, commonly every other day rather than daily
  • At a 2 mL fill on a 5 mg vial (2.5 mg/mL), 0.25 mg is a 0.1 mL draw (10 units)

Short courses, inject slowly

  • Run in short courses of around 2 weeks
  • LL-37 can sting at the injection site, so inject slowly
  • Dosing data is limited, so start at the low end

Dosing detail

  • Common dose is 0.1 mg to 0.5 mg, often every other day.
  • An antimicrobial peptide studied for immune and gut applications.
  • Run in short courses (about 2 weeks) rather than long continuous use.
  • Can sting; inject slowly. Start low, since dosing data is thinner than for the mainstream peptides.

Duration

  • Short courses of around 2 weeks.

Notes

  • An antimicrobial peptide studied for immune and gut applications.
  • Can sting at the injection site; inject slowly.
  • Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard